A rare case of D-penicillamine induced Myasthenia Gravis
BJKines - National Journal of Basic & Applied Sciences · 08.06.2026 · 18 · 34-36
DOI: 10.25259/bjkines_5_2026 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJKines - National Journal of Basic & Applied Sciences, online erschienen am 08.06.2026. Verfasst von Nilima K. Shah und 4 weiteren Autor:innen. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
D-Penicillamine (DPA) is a chelating agent widely used for Wilson’s disease, with Myasthenia gravis (MG) reported in approximately 1–7% of treated patients. The proposed mechanism involves immune dysregulation through modification of histocompatibility complex (MHC) molecules, triggering autoimmunity against acetylcholine receptors. DPA–induced MG may occur months to years (6–96 months) after therapy initiation, particularly in Wilson’s Disease patients, and often presents with isolated ocular symptoms with good response to pyridostigmine and clinical remission within one year after DPA treatment cessation.
Zitieren
APA
Shah, N. K., Parmar, J., Solanki, M., Patel, S., & Gojiya, M. (2026). A rare case of D-penicillamine induced Myasthenia Gravis. BJKines - National Journal of Basic & Applied Sciences, 18, 34-36. https://doi.org/10.25259/bjkines_5_2026
Vancouver
Shah NK, Parmar J, Solanki M, Patel S, Gojiya M. A rare case of D-penicillamine induced Myasthenia Gravis. BJKines - National Journal of Basic & Applied Sciences. 2026;18:34-36. doi:10.25259/bjkines_5_2026
BibTeX
@article{Shah2026,
author = {Shah, Nilima K. and Parmar, Jinal and Solanki, Milind and Patel, Shreyas and Gojiya, Madhav},
title = {A rare case of D-penicillamine induced Myasthenia Gravis},
journal = {BJKines - National Journal of Basic & Applied Sciences},
year = {2026},
volume = {18},
pages = {34--36},
doi = {10.25259/bjkines_5_2026}
}
EUVIMED